Rossano Joseph W, Cabrera Antonio G, Shaddy Robert E
1Department of Pediatrics, Section of Cardiology, The Perelman School of Medicine at the University of Pennsylvania, The Children's Hospital of Philadelphia, Philadelphia, PA. 2Department of Pediatrics, Section of Cardiology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX.
Pediatr Crit Care Med. 2016 Aug;17(8 Suppl 1):S171-7. doi: 10.1097/PCC.0000000000000813.
Although there have been tremendous advancements in the care of severe pediatric cardiovascular disease, heart transplantation remains the standard therapy for end-stage heart disease in children. As such, these patients comprise an important and often complex subset of patients in the ICU. The purpose of this article is to review the causes and management of allograft dysfunction and the medications used in the transplant population.
MEDLINE, PubMed, and Cochrane Database of systemic reviews.
Pediatric heart transplant recipients represent a complex group of patients that frequently require critical care. Their immunosuppressive medications, while being vital to maintenance of allograft function, are associated with significant short- and long-term complications. Graft dysfunction can occur from a variety of etiologies at different times following transplantation and remains a major limitation to long-term posttransplant survival.
尽管小儿重症心血管疾病的治疗已取得巨大进展,但心脏移植仍是儿童终末期心脏病的标准治疗方法。因此,这些患者是重症监护病房中一个重要且通常较为复杂的患者亚群。本文旨在综述移植心脏功能障碍的病因、管理以及移植人群中使用的药物。
医学文献数据库(MEDLINE)、医学期刊数据库(PubMed)和系统评价的考克兰数据库。
小儿心脏移植受者是一组复杂的患者群体,经常需要重症监护。他们的免疫抑制药物虽然对维持移植心脏功能至关重要,但会带来显著的短期和长期并发症。移植心脏功能障碍可在移植后的不同时间由多种病因引起,并且仍然是移植后长期生存的主要限制因素。